Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study

PURPOSE: To compare the efficacy and safety of ranibizumab 0.5 mg with or without verteporfin photodynamic therapy in Japanese patients with polypoidal choroidal vasculopathy over 12 months. STUDY DESIGN: EVEREST II was a 24-month, Phase IV, multicenter, randomized, double-masked study in Asian pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Kanji, Ohji, Masahito, Terasaki, Hiroko, Honda, Shigeru, Margaron, Philippe, Guerin, Tadhg, Yuzawa, Mitsuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145359/
https://www.ncbi.nlm.nih.gov/pubmed/30271112
http://dx.doi.org/10.2147/OPTH.S171015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145359/
https://www.ncbi.nlm.nih.gov/pubmed/30271112
http://dx.doi.org/10.2147/OPTH.S171015

Ejemplares similares